Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
NCT04438382Phase 2Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of infliximab in pneumonitis (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Pneumonitis Response Rate at 28 days. Started Jan 2021; status: terminated.
02
Drugs
infliximab
03
Conditions
pneumonitis
Beyond the preview
Go deeper on NCT04438382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438382.